www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

February 19, 2014

PDF Version

Supporting Materials:
FM_08_14UK_19022014.pdf

 

Copenhagen, 2014-02-19 10:26 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 28(a) of the Danish Securities Trading Act, ALK-Abelló A/S shall report transactions under securities identification code (ISIN) DK00060027142, ALK-Abelló B shares under the symbol ALK B:

  

NameFlemming Steen Jensen
ReasonMember of the Board of Management
TransactionExercise of share options
(purchase of shares — cash settlement)
Trading date18 February 2014
MarketNASDAQ OMX Copenhagen A/S
Number21,075
Share price413
Market valueDKK 8,704,004

  

NameFlemming Steen Jensen
ReasonMember of the Board of Management
TransactionExercise of share options
(sale of shares — cash settlement)
Trading date18 February 2014
MarketNASDAQ OMX Copenhagen A/S
Number21,075
Share price714
Market valueDKK 15,047,550

 
Calculation of share price

When calculating the share price in connection with exercise of options, the purchase price is based on the price at grant adjusted upwards annually by 2.5% less dividend payments.

The Board of Directors has decided that these share options will be settled in cash and the final settlement is based on the average price of the Company's B shares quoted on NASDAQ OMX Copenhagen A/S in a period of ten days.

ALK-Abelló A/S

Contact persons:

Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations:
Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

 

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved